Cargando…
Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report
BACKGROUND: Prostate cancer (PC) is currently the most common malignant tumor of the genitourinary system in men. Radical prostatectomy (RP) is recommended for the treatment of patients with localized PC. Adjuvant hormonal therapy (AHT) can be administered postoperatively in patients with high-risk...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130988/ https://www.ncbi.nlm.nih.gov/pubmed/37123314 http://dx.doi.org/10.12998/wjcc.v11.i11.2528 |
_version_ | 1785031078016188416 |
---|---|
author | Zou, Qian Shen, Rui-Lin Guo, Xiao Tang, Chen-Ye |
author_facet | Zou, Qian Shen, Rui-Lin Guo, Xiao Tang, Chen-Ye |
author_sort | Zou, Qian |
collection | PubMed |
description | BACKGROUND: Prostate cancer (PC) is currently the most common malignant tumor of the genitourinary system in men. Radical prostatectomy (RP) is recommended for the treatment of patients with localized PC. Adjuvant hormonal therapy (AHT) can be administered postoperatively in patients with high-risk or locally advanced PC. Chemotherapy is a vital remedy for castration-resistant prostate cancer (CRPC), and may also benefit patients with PC who have not progressed to CRPC. CASE SUMMARY: A 68-year-old male was admitted to our hospital because of urinary irritation and dysuria with increased prostate-specific antigen (PSA) levels. After detailed examination, he was diagnosed with PC and treated with laparoscopic RP on August 3, 2020. AHT using androgen deprivation therapy (ADT) was performed postoperatively because of the positive surgical margin, extracapsular extension, and neural invasion but lasted only 6 mo. Unfortunately, he was diagnosed with rectal cancer about half a year after self-cessation of AHT, and was then treated with laparoscopic radical rectal resection and adjuvant chemotherapy using the capecitabine plus oxaliplatin (CapeOx) regimen. During the entire treatment process, the patient's PSA level first declined significantly after treatment of PC with laparoscopic RP and ADT, then rebounded because of self-cessation of ADT, and finally decreased again after CapeOx chemotherapy. CONCLUSION: CapeOx chemotherapy can reduce PSA levels in patients with high-risk locally advanced PC, indicating that CapeOx may be an alternative chemotherapy regimen for PC. |
format | Online Article Text |
id | pubmed-10130988 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-101309882023-04-27 Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report Zou, Qian Shen, Rui-Lin Guo, Xiao Tang, Chen-Ye World J Clin Cases Case Report BACKGROUND: Prostate cancer (PC) is currently the most common malignant tumor of the genitourinary system in men. Radical prostatectomy (RP) is recommended for the treatment of patients with localized PC. Adjuvant hormonal therapy (AHT) can be administered postoperatively in patients with high-risk or locally advanced PC. Chemotherapy is a vital remedy for castration-resistant prostate cancer (CRPC), and may also benefit patients with PC who have not progressed to CRPC. CASE SUMMARY: A 68-year-old male was admitted to our hospital because of urinary irritation and dysuria with increased prostate-specific antigen (PSA) levels. After detailed examination, he was diagnosed with PC and treated with laparoscopic RP on August 3, 2020. AHT using androgen deprivation therapy (ADT) was performed postoperatively because of the positive surgical margin, extracapsular extension, and neural invasion but lasted only 6 mo. Unfortunately, he was diagnosed with rectal cancer about half a year after self-cessation of AHT, and was then treated with laparoscopic radical rectal resection and adjuvant chemotherapy using the capecitabine plus oxaliplatin (CapeOx) regimen. During the entire treatment process, the patient's PSA level first declined significantly after treatment of PC with laparoscopic RP and ADT, then rebounded because of self-cessation of ADT, and finally decreased again after CapeOx chemotherapy. CONCLUSION: CapeOx chemotherapy can reduce PSA levels in patients with high-risk locally advanced PC, indicating that CapeOx may be an alternative chemotherapy regimen for PC. Baishideng Publishing Group Inc 2023-04-16 2023-04-16 /pmc/articles/PMC10130988/ /pubmed/37123314 http://dx.doi.org/10.12998/wjcc.v11.i11.2528 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Case Report Zou, Qian Shen, Rui-Lin Guo, Xiao Tang, Chen-Ye Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report |
title | Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report |
title_full | Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report |
title_fullStr | Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report |
title_full_unstemmed | Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report |
title_short | Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report |
title_sort | prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130988/ https://www.ncbi.nlm.nih.gov/pubmed/37123314 http://dx.doi.org/10.12998/wjcc.v11.i11.2528 |
work_keys_str_mv | AT zouqian prostatespecificantigenreductionaftercapecitabineplusoxaliplatinchemotherapyacasereport AT shenruilin prostatespecificantigenreductionaftercapecitabineplusoxaliplatinchemotherapyacasereport AT guoxiao prostatespecificantigenreductionaftercapecitabineplusoxaliplatinchemotherapyacasereport AT tangchenye prostatespecificantigenreductionaftercapecitabineplusoxaliplatinchemotherapyacasereport |